Hausdorff William P, Scheele Suzanne, Giersing Birgitte K
Center for Vaccine Innovation and Access, PATH, 455 Massachusetts Ave NW, Washington, DC 20001, USA.
Faculty of Medicine, Université Libre de Bruxelles, 1050 Brussels, Belgium.
Vaccines (Basel). 2022 Feb 12;10(2):282. doi: 10.3390/vaccines10020282.
The development and licensure of a safe and highly efficacious vaccine has been a priority in international public health circles for decades and would represent a great scientific achievement. Nonetheless, in the context of increasingly crowded and costly childhood immunization programs, and with a myriad of other new and improved vaccines currently or soon on the market, there is no guarantee that even a highly effective vaccine would become a priority for adoption and introduction by the low- and middle-income countries that could benefit from it the most. We discuss here some of the major determinants and questions regarding the introduction of vaccines and the importance of developing a succinct, compelling public health value proposition.
几十年来，研发和批准一种安全且高效的疫苗一直是国际公共卫生界的首要任务，这将是一项重大的科学成就。然而，在儿童免疫规划日益拥挤且成本高昂的背景下，以及目前或即将上市的大量其他新型和改良疫苗的情况下，即使是一种高效疫苗，也不能保证会成为最能从中受益的低收入和中等收入国家采用和引入的优先选择。我们在此讨论一些关于疫苗引入的主要决定因素和问题，以及制定一个简洁、有说服力的公共卫生价值主张的重要性。
